Stella M. Davies, MBBS, PhD, MRCP
- Director, Division of Bone Marrow Transplantation and Immune Deficiency
- Institute Co-Executive Director, Cancer and Blood Diseases Institute
- Jacob G. Schmidlapp Endowed Chair
- Professor, UC Department of Pediatrics
About
Biography
As a doctor specializing in bone marrow transplantation, I enjoy forming long-term relationships with patients and their families and traveling with them on their journey.
Everyone’s path is different, and our team of doctors and nurses is committed to exceptional care. We deliver personalized treatments to each child and adolescent — one size fits no one!
I am honored to be president-elect of the American Society of Transplantation and Cellular Therapy, the professional society for bone marrow transplant specialists.
In my research, my colleagues and I focus on finding out what causes complications after bone marrow transplantation and determine better ways to fix these complications.
In my spare time, I enjoy supporting my daughter, a Cincinnati Rollergirl, at roller derby bouts.
MBBS: University of Newcastle-Upon-Tyne, England, 1981.
Clinical and Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1981 to 1985.
PhD: University of Newcastle-Upon-Tyne, England, 1989.
Pediatric Fellowship: University of Minnesota, Minneapolis, MN, 1989 to 1993.
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Childhood cancer etiology: recent reports. Pediatric Blood and Cancer. 2003; 40:35-38.
Is it possible to catch leukaemia from a cat?. The Lancet. 1994; 344:1580.
Epidemiology of childhood leukemia, with a focus on infants. Epidemiologic Reviews. 1994; 16:243-272.
Maintenance of genomic imprinting at the IGF2 locus in hepatoblastoma. Cancer Research. 1993; 53:4781-4783.
Bone marrow transplant for acute leukaemia. Best Practice & Research: Clinical Haematology. 1991; 4:483-510.
Kinetics of DNases after hematopoietic stem cell transplant. 2025; 2:100055.
Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. 2025; 1.
Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity. 2025; 1.
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Blood Advances. 2025; 9:1927-1939.
Engraft: A Collaborative Learning Health Network for Enhanced Transplant and Cellular Therapy Outcomes. Transplantation and Cellular Therapy. 2025; 31:123-134.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey